Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.1.1 (
asparaginase
)
2,695
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Connective tissue growth factor (
CTGF
/CCN2) is involved in extracellular matrix production, tumor cell proliferation, adhesion, migration, and metastasis. Recent studies have shown that
CTGF
expression is elevated in precursor B-acute lymphoblastic leukemia (ALL) and that increased expression of
CTGF
is associated with inferior outcome in B-ALL. In this study, we characterized the functional role and downstream signaling pathways of
CTGF
in ALL cells. First, we utilized lentiviral shRNA to knockdown
CTGF
in RS4;11 and REH ALL cells expressing high levels of
CTGF
mRNA. Silencing of
CTGF
resulted in significant suppression of leukemia cell growth compared to control vector, which was associated with AKT/mTOR inactivation and increased levels of cyclin-dependent kinase inhibitor p27.
CTGF
knockdown sensitized ALL cells to vincristine and methotrexate. Treatment with an anti-
CTGF
monoclonal antibody, FG-3019, significantly prolonged survival of mice injected with primary xenograft B-ALL cells when co-treated with conventional chemotherapy (vincristine,
L-asparaginase
and dexamethasone). Data suggest that
CTGF
represents a targetable molecular aberration in B-ALL, and blocking
CTGF
signaling in conjunction with administration of chemotherapy may represent a novel therapeutic approach for ALL patients.
...
PMID:Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth. 2415 79